Celltrion, Inc.
Research Celltrion, Inc. (068270) on Bullrun: market cap KRW 43.73T, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker068270
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 43.73T
- Dividend yield0.4%
- Financial periodQ1 2026
- RevenueKRW 1.14T
- Net incomeKRW 346.14B
- Free cash flowKRW 135.82B
- Gross margin59.9%
Valuation Snapshot
latest market cap is KRW 43.73T; dividend yield is 0.4%.
Peer valuation comparison
Latest dividend yield is 0.37% versus a Healthcare sector median of 2.11% (82.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | KRW 4.16T | KRW 1.03T | KRW 314.32B | 59.3% | n/a | KRW 1.12T | KRW 3.73T | KRW 17.21T |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | KRW 43.73T | n/a | 0.4% | 714.29 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 714.29 KRW, yield 0.4%.
About Celltrion, Inc.
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Celltrion, Inc.'s market cap?
Celltrion, Inc.'s market capitalization is KRW 43.73T.
Does Celltrion, Inc. pay a dividend?
Celltrion, Inc. has a dividend yield of 0.4%.
What does Celltrion, Inc. do?
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products.